MetaOptima is an intelligent dermatology and skin analytics company. Its product is a skin imaging and analytics SaaS platform that has world leading skin cancer AI detection accuracy and sells to integrated health systems, hospitals, telemedicine companies and skin clinics globally. MetaOptima received a breakthrough designation approval from the FDA after entering the US market in 2021 and is expecting De Novo Class II approval by the end of 2022 which would expand its Total Addressable Market (“TAM”). MetaOptima raised $6.5M for series A in 2018 from Skip Capital and AirTree from Australia. Since MetaOptima’s business has shifted to North America and about half of Annual Recurring Revenue (“ARR”) earned in the USA, with the rest spread across Europe and Asia, MetaOptima is seeing good SaaS metrics (e.g., Net Revenue Retention (“NRR”) >100%) and USA ARR grew 125% YoY to Dec-21 during the pandemic. It has executed better than expected on its US pipeline and now has a solid 2022/23 US pipeline including the major US health systems and pharmacy chains.